Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $203.45

Insmed, Inc. (NASDAQ:INSM) has received an average recommendation of “Buy” from the twenty-four ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nineteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $204.2381.

A number of analysts have recently weighed in on INSM shares. HC Wainwright reduced their target price on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Cantor Fitzgerald raised their target price on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Rothschild & Co Redburn set a $263.00 target price on shares of Insmed in a report on Thursday, December 4th. Finally, Leerink Partners restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th.

Insider Buying and Selling

In other news, Director Leo Lee sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $195.90, for a total value of $14,692,500.00. Following the transaction, the director owned 54,677 shares in the company, valued at approximately $10,711,224.30. This represents a 57.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO William Lewis sold 19,215 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 248,253 shares of company stock worth $44,322,342 in the last 90 days. 3.00% of the stock is owned by company insiders.

Institutional Trading of Insmed

Several institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. Kingsview Wealth Management LLC increased its holdings in Insmed by 2.7% in the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 60 shares in the last quarter. Choreo LLC raised its position in Insmed by 2.9% in the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 69 shares during the period. Finally, ORG Partners LLC boosted its holdings in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 74 shares during the last quarter.

Insmed Trading Up 1.8%

NASDAQ INSM opened at $148.75 on Wednesday. The firm has a market capitalization of $31.72 billion, a PE ratio of -24.03 and a beta of 1.11. The stock’s 50 day moving average is $169.05 and its 200 day moving average is $161.50. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.